IPM Take
Europe does not have a shortage of cardiovascular AI models.
It has a shortage of evidence that they will work safely, consistently and usefully once they leave the institution where they were developed.
That is the problem CHAIN is trying to solve.
The new European Cardiovascular Health Data and AI Network brings together 53 partners from 20 countries under the coordination of the European Society of Cardiology, supported by €20 million in EU4Health funding. Over three years, it will build a federated infrastructure for testing, validating and deploying AI across prevention, early diagnosis and cardiovascular care.
The most politically interesting part is not the algorithms.
It is the attempt to standardise trust.
Validated tools are expected to enter a European repository accompanied by “AI passports” describing performance, safety and clinical suitability. In effect, Europe is trying to create a more legible evidence trail around medical AI, so hospitals and health authorities are not forced to judge every system from marketing claims, single-centre publications or vendor documentation alone.
That matters because the next bottleneck in clinical AI is no longer invention.
It is implementation.
The real question is whether CHAIN can make validation portable across borders, hospitals and populations without reducing complex regulatory and clinical evidence to a digital badge.
If it can, cardiovascular AI may finally start behaving less like an endless collection of promising pilots and more like health-system infrastructure.
Executive Summary
The European Cardiovascular Health Data and AI Network, known as CHAIN, has been launched as a 36-month EU-funded initiative to accelerate the safe adoption of artificial intelligence in cardiovascular and related non-communicable disease care.
The project is coordinated by the European Society of Cardiology and includes 53 partners from 20 European countries, spanning hospitals, universities, research organisations, health ministries, technology companies and patient groups.
CHAIN receives €20 million in EU funding through the EU4Health Programme.
Its core objective is to create a federated ecosystem linking hospitals, health-data hubs and disease registries so that AI tools can be tested and validated across multiple European settings without requiring all underlying health data to be pooled into a single central database.
The infrastructure is designed to align with the European Health Data Space and with the broader regulatory environment created by the EU AI Act and medical-device legislation.
The project will build on the ESC’s EuroHeart registry network and will implement six real-world use cases across 13 countries, covering cardiovascular risk stratification, early disease detection, clinical decision support and the management of complex disease.
A European repository of validated AI systems is also planned. Tools included in the repository will be accompanied by AI passports documenting evidence on performance, safety and suitability for clinical use.
CHAIN is part of the implementation architecture surrounding the EU Safe Hearts Plan and reflects a wider European shift from funding individual AI prototypes toward building the data, validation and governance infrastructure required for deployment at scale.
Why it matters
- HTA bodies: AI assessment increasingly needs evidence that extends beyond headline accuracy metrics. CHAIN could help generate comparative, multi-country evidence on performance, generalisability, clinical utility and implementation context. The value for HTA will depend on whether its validation framework captures outcomes relevant to real healthcare decisions rather than becoming another technical certification layer.
- Payers: Health systems face growing pressure to purchase AI without clear evidence that it improves outcomes, workflow or resource use. A common European validation infrastructure could reduce duplicated evaluation and give payers stronger evidence on where AI genuinely adds value, but reimbursement decisions will still require economic evidence beyond algorithm performance.
- Industry / innovation partners: CHAIN could offer developers something Europe currently lacks at scale: access to a cross-border pathway for real-world validation. That could make it easier for credible tools to move beyond single-centre pilots, while raising the evidence threshold for companies whose models do not generalise across populations and health systems.
Cardiovascular AI has reached an awkward stage of maturity.
The field has no shortage of impressive demonstrations. Algorithms can interpret ECGs, flag imaging abnormalities, estimate cardiovascular risk, predict deterioration and support increasingly complex clinical decisions. Some are already embedded in routine care.
But Europe has accumulated far more AI prototypes than it has examples of AI scaled safely across national health systems.
That gap between technical performance and clinical deployment is where CHAIN enters.
The European Cardiovascular Health Data and AI Network is being built not as another stand-alone algorithm project, but as an attempt to create the infrastructure around algorithms. Led by the European Society of Cardiology, the initiative brings together 53 organisations from 20 countries and has received €20 million through the EU4Health Programme.
Over the next three years, its job is to answer a problem that has frustrated digital health for years: how do you know that an AI system that worked in one hospital will still work when it meets another country’s patients, another electronic health-record system, another clinical workflow and another mix of disease?
That problem is particularly acute in cardiovascular medicine.
Heart disease may be a shared European burden, but cardiovascular datasets are anything but uniform. Countries collect different variables. Hospitals use different systems. Imaging and laboratory practices vary. Patient populations differ in age, ethnicity, comorbidity and socioeconomic background. A model trained within one of those environments can perform very differently when transported into another.
That is why CHAIN’s emphasis on federation matters.
The intention is not to move every European cardiovascular dataset into one enormous central repository. Instead, hospitals, registries and data hubs would remain connected within a distributed ecosystem that allows AI to be evaluated across multiple settings while data governance remains aligned with European rules.
That approach fits directly with the philosophy of the European Health Data Space, which is creating a framework for both the clinical use and secondary reuse of health data across the EU.
But health-data access alone does not solve the AI problem.
A bad algorithm can be trained on excellent data.
A highly accurate model can still be clinically useless.
And an AI tool that performs well in a controlled validation dataset may fail when clinicians have to interpret its output under time pressure in ordinary practice.
CHAIN therefore puts unusual emphasis on what happens after technical development.
Six real-world use cases will be tested across 13 countries, spanning prevention, early detection, clinical decision support and complex cardiovascular care. The objective is to generate evidence under different healthcare conditions rather than relying solely on controlled development environments.
That is also where the project begins to look less like a research consortium and more like a piece of European health policy.
The EU has already spent heavily on AI and health-data projects. The harder challenge now is deciding which innovations deserve to move into ordinary healthcare.
CHAIN’s proposed answer is the “AI passport”.
Validated tools placed in the planned European repository would carry information on their performance, safety and suitability for particular clinical settings. For a hospital manager or health authority considering whether to adopt an AI system, that could provide a more structured picture of what has actually been tested, in which populations and under what conditions.
The idea is attractive because medical AI currently suffers from an information asymmetry.
Developers know how their system was built.
Hospitals often know much less.
Published accuracy metrics may come from selected datasets. External validation may be limited. Subgroup performance may not be transparent. Local workflow requirements may only become apparent after procurement.
An AI passport could make some of that evidence easier to interrogate.
But it also raises a harder question: what exactly should count as trustworthy?
Sensitivity and specificity are not enough.
A clinically credible AI system needs evidence that it performs across different populations, that its error profile is understood, that clinicians know when not to trust it, that it integrates into workflow without creating new safety risks and, ideally, that its use improves an outcome that matters.
That outcome may not always be mortality.
It could be earlier diagnosis, fewer unnecessary tests, faster treatment, better referral, reduced workload or more equitable access.
But something beyond algorithmic accuracy ultimately has to improve.
CHAIN will therefore succeed only if its validation infrastructure remains demanding enough to distinguish technological performance from clinical value.
The political timing is significant.
The project is being launched as the European Health Data Space, the AI Act and evolving medical-device rules are increasingly shaping the environment in which clinical AI must operate. The Safe Hearts Plan has also placed digitalisation and AI inside a broader European cardiovascular strategy rather than treating them as separate innovation policy.
That convergence matters.
Europe is effectively trying to build a regulatory and data ecosystem at the same time that the technology itself is evolving.
The risk is bureaucracy.
If every new AI tool has to navigate multiple overlapping validation, data-governance, medical-device and procurement systems, European hospitals could struggle to adopt useful innovations quickly.
The opposite risk is worse.
If adoption moves faster than evidence, health systems could spend heavily on tools that perform unpredictably outside their development setting or widen existing inequalities because the populations used to build them were not representative.
CHAIN is trying to occupy the difficult space between those two extremes.
Its relationship with EuroHeart may help.
The ESC’s registry initiative already provides standardised cardiovascular data frameworks and a cross-national infrastructure for monitoring care and outcomes. CHAIN can use that foundation rather than starting with entirely fragmented data environments.
That is strategically important because standardisation is one of the least glamorous but most consequential problems in clinical AI.
Algorithms cannot scale cleanly if the meaning of the underlying variables changes from one system to another.
In that sense, CHAIN’s real product may not ultimately be a particular AI tool.
It may be a set of common expectations about what cardiovascular AI needs to prove before Europe trusts it.
That could have consequences well beyond cardiology.
Cancer imaging, pathology, rare disease and hospital decision support face many of the same problems: fragmented data, inconsistent validation, uncertainty over generalisability and difficulty moving from research to procurement.
If the cardiovascular model works, it could become a template for other areas of European medicine.
But that is still an “if”.
CHAIN is at the beginning of a three-year programme. Its use cases have to produce evidence. Its federation model has to work across national infrastructures. Its AI passports have to prove useful rather than decorative. And hospitals still need to demonstrate that validated tools can be integrated into routine care without adding cost and complexity for little clinical return.
Europe has spent years asking what artificial intelligence could do for medicine.
CHAIN reflects a more mature question.
Which AI can be trusted, where does it actually add value, and what evidence should a health system demand before putting it in front of a patient?
